Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 1371

Sort by

Sort Order Select

Journal Articles

Integrative genomic analysis of pediatric T-cell lymphoblastic lymphoma reveals candidates of clinical significance

Blood (2021) 137 (17): 2347–2359.

https://doi.org/10.1182/blood.2020005381

Published: 2021

Includes: Supplemental data

Journal Articles

The different flavors and splices of MCL

Oliver Weigert

Blood (2020) 136 (5): 526–527.

https://doi.org/10.1182/blood.2020005591

Published: 2020

Journal Articles

CD49d promotes disease progression in chronic lymphocytic leukemia: new insights from CD49d bimodal expression

Blood (2020) 135 (15): 1244–1254.

https://doi.org/10.1182/blood.2019003179

Published: 2020

Includes: Supplemental data

Journal Articles

IKZF1 deletions in pediatric acute lymphoblastic leukemia: still a poor prognostic marker?

Martin Stanulla, Hélène Cavé, Anthony V. Moorman

Blood (2020) 135 (4): 252–260.

https://doi.org/10.1182/blood.2019000813

Published: 2020

Journal Articles

Natural-Killer Cell Cytotoxicity Is a Diagnostic and Prognostic Marker in Adult Patients with Secondary Hemophagocytic Lymphohistiocytosis: Results from a Prospective Phase II Observational Study

Han Bi Lee, Jae-Ho Yoon, MD PhD, Gi June Min, MD, Sung-Soo Park, Silvia Park, Sung-Eun Lee, MD, Ki-Seong Eom, MD PhD, Yoo-Jin Kim, MD PhD, Seok Lee, MD PhD, Hee-Je Kim, MD PhD, Chang-Ki Min, MD PhD, Seok-Goo Cho, MD PhD, Jong Wook Lee, MD PhD

Blood (2019) 134 (Supplement_1): 2331.

https://doi.org/10.1182/blood-2019-129676

Published: 2019

Journal Articles

A Population-Based Analysis of Predictors of Survival and Trends in Outcomes of Elderly Patients with Multiple Myeloma (MM)

Vivek Kumar, MD, M.B.,B.S., Meghna Ailawadhi, MD, Mays F Abdulazeez, MBBS, Suman Biswas, MD, Sri Lekha Bodepudi, Leyla Bojanini, MD, Vivek Roy, MD, Taimur Sher, MD, Victoria R. Alegria, Rami Manochakian, MD, Aneel Paulus, MD, Asher A. Chanan-Khan, MD, Sikander Ailawadhi, MD

Blood (2019) 134 (Supplement_1): 4779.

https://doi.org/10.1182/blood-2019-125156

Published: 2019

Journal Articles

Recurrent Patterns of Clonal Evolution in Relapsed-Refractory DLBCL Following Treatment with R-CHOP

Blood (2019) 134 (Supplement_1): 921.

https://doi.org/10.1182/blood-2019-127399

Published: 2019

Journal Articles

Analysis of Mutational Landscape in Systemic Anaplastic Large Cell Lymphoma Identifies Novel Prognostic Markers

Blood (2019) 134 (Supplement_1): 1490.

https://doi.org/10.1182/blood-2019-126501

Published: 2019

Journal Articles

Prognostic Impact of the Baseline Immunologic Profile in Patients with Aggressive B Non-Hodgkin Lymphomas

Safaa M. Ramadan, PhD MD, Giusy Ceparano, MD, Alessandro Cignetti, MD PhD, Simona Sammassimo, MD, Vincenzo Bagnardi, Eleonora Pagan, Daniela Gottardi, MD, Stefano Fiori, MD, Rita Passerini, Tommaso Radice, MD, Giuseppe Saglio, MD, Corrado Tarella, MD

Blood (2019) 134 (Supplement_1): 1522.

https://doi.org/10.1182/blood-2019-132237

Published: 2019

Journal Articles

A Circular RNA Molecule, circRAB11FIP1, Is Associated with TP53 Mutations and Is of Potential Prognostic and Functional Significance in Mantle Cell Lymphoma: Data from the Nordic MCL2 and MCL3 Studies

Mette Dahl, MD, Simon Husby, MD, Christian Winther Eskelund, MD, Christophe Côme, PhD, Sara Ek, PhD Professor, Arne Kolstad, MD PhD, Riikka Räty, PhD Associate professor, Mats Jerkeman, MD Professor, Christian H. Geisler, MD PhD, Lasse Sommer Kristensen, PhD Assistant professor, Kirsten Grønbæk, Professor, MD DMSc

Blood (2019) 134 (Supplement_1): 1495.

https://doi.org/10.1182/blood-2019-123989

Published: 2019

Journal Articles

MN1 Expression Is an Indepedent Prognostic Marker in FLT3-Mutated Acute Myeloid Leukemia and Is Involved in the Resistance to FLT3 Inhibitors

Diego A Pereira-Martins, MSc, Juan L Coelho-Silva, BSc, MSc, Isabel Weinhäuser, MSc, Carol Hassibe Thomé, César Alexander Ortiz Rojas, BSc, Luíse A A Simões, BSc, Fabiola Traina, MD PhD, Michael Heuser, MD, Arnold Ganser, MD, Antonio R. Lucena-Araujo, PhD, Eduardo M Rego, MD PhD

Blood (2019) 134 (Supplement_1): 1403.

https://doi.org/10.1182/blood-2019-131542

Published: 2019

Journal Articles

PRAME Expression Is Correlated with Treatment Outcome and Specific Features of the Tumor Microenvironment in Classical Hodgkin Lymphoma

Katsuyoshi Takata, MD PhD, Lauren C. Chong, MSc, Avinash Thakur, PhD, Tomohiro Aoki, MD PhD, Anja Mottok, MD PhD, Elizabeth Chavez, BSc, Cg RT, Pedro Farinha, MD PhD, Graham W Slack, MD, Pamela Hoodles, Sohrab P Shah, David W. Scott, MBChB, PhD, Christian Steidl, MD

Blood (2019) 134 (Supplement_1): 1509.

https://doi.org/10.1182/blood-2019-129730

Published: 2019

Journal Articles

Combining Gene Expression Profiling and Artificial Intelligence to Diagnose B-Cell Non-Hodgkin Lymphoma

Victor Bobée, PharmD, Fanny Drieux, MD, Vinciane Marchand, Vincent Sater, Liana Veresezan, MD, Jean-Michel Picquenot, MD, Pierre-Julien Viailly, Marie-delphine Lanic, Mathieu Viennot, Elodie Bohers, PhD, Lucie Oberic, MD, Christiane Copie-Bergman, MD PhD, Thierry Jo Molina, MD PhD, Philippe Gaulard, MD PhD, Corinne Haioun, MD PhD, Gilles A. Salles, MD PhD, Herve Tilly, MD PhD, Fabrice Jardin, Philippe Ruminy, PhD

Blood (2019) 134 (Supplement_1): 1476.

https://doi.org/10.1182/blood-2019-122405

Published: 2019

Journal Articles

Interim Circulating Tumor DNA As a Prognostic Biomarker in the Setting of Interim PET-Based Adaptive Therapy for DLBCL

Charles Macaulay, MSc, BA, Stefan Alig, MD, David M. Kurtz, MD PhD, Michael C. Jin, BS, Stephen Opat, Joanne Soo, MD, Brian Sworder, MD PhD, Mark S. Hertzberg, MD PhD, Maher K. Gandhi, PhD, Maximilian Diehn, MD PhD, Ash A. Alizadeh, MD PhD

Blood (2019) 134 (Supplement_1): 1600.

https://doi.org/10.1182/blood-2019-131278

Published: 2019

Journal Articles

Daratumumab Monotherapy for Patients with Relapsed or Refractory (R/R) Natural Killer/T-Cell Lymphoma (NKTCL), Nasal Type: Updated Results from an Open-Label, Single-Arm, Multicenter Phase 2 Study

Blood (2019) 134 (Supplement_1): 1568.

https://doi.org/10.1182/blood-2019-123446

Published: 2019

Journal Articles

IL-33 Therapy Prevents Acute Lung Injury after Transplantation Via IL-9-Producing Type 2 Innate Lymphoid Cells Induction

Hua Jiang, PhD, Abdulraouf Ramadan, PhD, Becquet Laurine, MS, Tu Szu-Wei, Hong Liu, MS, Courtney Rowan, MD, Xiaowen Liu, PhD, Huanmei Wu, PhD, Jun Wan, PhD, Sophie Paczesny, MD PhD

Blood (2019) 134 (Supplement_1): 583.

https://doi.org/10.1182/blood-2019-123821

Published: 2019

Journal Articles

TP53 State Dictates Genome Stability, Clinical Presentation and Outcomes in Myelodysplastic Syndromes

Elsa Bernard, PhD, Yasuhito Nannya, MD PhD, Tetsuichi Yoshizato, MD PhD, Robert P. Hasserjian, MD, Ryunosuke Saiki, Yusuke Shiozawa, MD PhD, Sean M. Devlin, PhD, Heinz Tuechler, Araxe Sarian, Luca Malcovati, MD, Francesc Sole, PhD, Detlef Haase, MD, Maria Creignou, Max Levine, MS, Ulrich Germing, MD, Catherine Cargo, MB, FRCPath, Yanming Zhang, MD, Juan Medina, MS, Juan E. Arango Ossa, BS, Julie Schanz, MD PhD, Arjan van de Loosdrecht, MD PhD, Martin Jädersten, MD PhD, John M. Bennett, MD, Magnus Tobiasson, MD PhD, Olivier Kosmider, PharmD, PhD, Matilde Y Follo, PhD, Felicitas Thol, MD, Ronald F Pinheiro, MD, Valeria Santini, MD, Ioannis Kotsianidis, Jacqueline Boultwood, Fabio PS Santos, MD, Senji Kasahara, MD PhD, Takayuki Ishikawa, MD PhD, Hisashi Tsurumi, MD PhD, Akifumi Takaori-Kondo, MD PhD, Toru Kiguchi, Chantana Polprasert, MD, Virginia M. Klimek, MD, Michael R. Savona, MD, Monika Belickova, PhD, Christina Ganster, Lionel Ades, MD PhD, Matteo Giovanni Della Porta, MD, Alexandra Smith, PhD, Yesenia Werner, Minal A Patel, MPH, Agnes Viale, PhD, Katelynd Vanness, Donna S Neuberg, ScD, Kristen E. Stevenson, MS, Kamal Menghrajani, MD, Kelly Bolton, MD PhD, Pierre Fenaux, MD PhD, Andrea Pellagatti, Uwe Platzbecker, MD, Michael Heuser, MD, Peter Valent, MD, Shigeru Chiba, MD PhD, Yasushi Miyazaki, MD PhD, Carlo Finelli, Maria Teresa Voso, MD, Lee-Yung Shih, MD, Michaela Fontenay, MD PhD, Joop H. Jansen, PhD, José Cervera, MD PhD, Yoshiko Atsuta, MD PhD, Norbert Gattermann, MD, Benjamin L. Ebert, MD PhD, Rafael Bejar, MD PhD, Peter L Greenberg, MD, Mario Cazzola, MD, Eva Hellstrom Lindberg, MD PhD, Seishi Ogawa, MD PhD, Elli Papaemmanuil, PhD

Blood (2019) 134 (Supplement_1): 675.

https://doi.org/10.1182/blood-2019-129392

Published: 2019

Journal Articles

High Metabolic Heterogeneity on Baseline 18F-FDG PET/CT Predicts Worse Prognosis of Newly Diagnosed Diffuse Large B-Cell Lymphoma

Hajime Senjo, MD, Kenji Hirata, MD PhD, Koh Izumiyama, MD PhD, Koichiro Minauchi, MD, Kazuo Itoh, Eriko Tsukamoto, Akio Mori, Shuichi Ota, Daigo Hashimoto, Takanori Teshima, MD

Blood (2019) 134 (Supplement_1): 488.

https://doi.org/10.1182/blood-2019-124390

Published: 2019

Journal Articles

CARMA1 Is Required for Notch1-Induced NF-κb Activation in T-Cell Acute Lymphoblastic Leukemia

Rong Wang, Ninghan Zhang, Yuan Feng, Tingting Shao, Huihui Zhang, Ting Pan, Jianlin Qiao, PhD, Kailin Xu, MD, Mingshan Niu, PhD

Blood (2019) 134 (Supplement_1): 1260.

https://doi.org/10.1182/blood-2019-125796

Published: 2019

Journal Articles

NPM1 Quantitative Monitoring of Minimal Residual Disease in Acute Myeloid Leukemia Allows More Precise Selection of Patients for Allogeneic Stem Cell Transplantation without Affecting Their Survival

Yishai Ofran, MD, Ronit Leiba, Dina Rosenberg, Israel Henig, MD, Dana Yehudai-Ofir, MD, Nuhad Haddad, MD, Riva Fineman, MD, Avraham Frisch, MD, Doaa Okasha, MD, Yariv Carasso, MD, Tsila Zuckerman, MD, Nurit Horesh, MD

Blood (2019) 134 (Supplement_1): 2603.

https://doi.org/10.1182/blood-2019-126553

Published: 2019

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Integrative genomic analysis of pediatric T-cell lymphoblastic lymphoma reveals candidates of clinical significance

The different flavors and splices of MCL

CD49d promotes disease progression in chronic lymphocytic leukemia: new insights from CD49d bimodal expression

IKZF1 deletions in pediatric acute lymphoblastic leukemia: still a poor prognostic marker?

Natural-Killer Cell Cytotoxicity Is a Diagnostic and Prognostic Marker in Adult Patients with Secondary Hemophagocytic Lymphohistiocytosis: Results from a Prospective Phase II Observational Study

A Population-Based Analysis of Predictors of Survival and Trends in Outcomes of Elderly Patients with Multiple Myeloma (MM)

Recurrent Patterns of Clonal Evolution in Relapsed-Refractory DLBCL Following Treatment with R-CHOP

Analysis of Mutational Landscape in Systemic Anaplastic Large Cell Lymphoma Identifies Novel Prognostic Markers

Prognostic Impact of the Baseline Immunologic Profile in Patients with Aggressive B Non-Hodgkin Lymphomas

A Circular RNA Molecule, circRAB11FIP1, Is Associated with TP53 Mutations and Is of Potential Prognostic and Functional Significance in Mantle Cell Lymphoma: Data from the Nordic MCL2 and MCL3 Studies

MN1 Expression Is an Indepedent Prognostic Marker in FLT3-Mutated Acute Myeloid Leukemia and Is Involved in the Resistance to FLT3 Inhibitors

PRAME Expression Is Correlated with Treatment Outcome and Specific Features of the Tumor Microenvironment in Classical Hodgkin Lymphoma

Combining Gene Expression Profiling and Artificial Intelligence to Diagnose B-Cell Non-Hodgkin Lymphoma

Interim Circulating Tumor DNA As a Prognostic Biomarker in the Setting of Interim PET-Based Adaptive Therapy for DLBCL

Daratumumab Monotherapy for Patients with Relapsed or Refractory (R/R) Natural Killer/T-Cell Lymphoma (NKTCL), Nasal Type: Updated Results from an Open-Label, Single-Arm, Multicenter Phase 2 Study

IL-33 Therapy Prevents Acute Lung Injury after Transplantation Via IL-9-Producing Type 2 Innate Lymphoid Cells Induction

TP53 State Dictates Genome Stability, Clinical Presentation and Outcomes in Myelodysplastic Syndromes

High Metabolic Heterogeneity on Baseline 18F-FDG PET/CT Predicts Worse Prognosis of Newly Diagnosed Diffuse Large B-Cell Lymphoma

CARMA1 Is Required for Notch1-Induced NF-κb Activation in T-Cell Acute Lymphoblastic Leukemia

NPM1 Quantitative Monitoring of Minimal Residual Disease in Acute Myeloid Leukemia Allows More Precise Selection of Patients for Allogeneic Stem Cell Transplantation without Affecting Their Survival

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only